GlassScriptPhysician profile
Matthew D Blake
NPI 1578191250
$3,397.88
in general payments reported to CMS, 2019-2025
31 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $255 · 2024: $419 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590 · Education: $915 · Travel and Lodging: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.39 |
| Education | $915.00 |
| Travel and Lodging | $892.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,834.03 | 2025 | |
| Abbvie INC. | $309.93 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $146.12 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $124.21 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $96.19 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $70.95 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $66.05 | 2025 | |
| Corcept Therapeutics | $63.76 | 2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $56.02 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $55.93 | 2024-2025 | Aristada, Lybalvi |
| Insulet Corporation | $54.25 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $45.40 | 2025 | |
| Lilly USA, LLC | $44.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $38.35 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $33.21 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.84 | 2023-2025 | Evenity, Enbrel, Tavneos |
| Phathom Pharmaceuticals, INC. | $30.39 | 2024-2025 | Voquezna |
| Pfizer INC. | $27.78 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.54 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $27.53 | 2024-2025 | Trintellix |
| Tandem Diabetes Care, INC. | $25.99 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $25.56 | 2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $24.94 | 2025 | Fanapt, Hetlioz |
| Dexcom, INC. | $23.89 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.66 | 2025 | Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.50 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $17.32 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $15.91 | 2023 | Rotateq, Gardasil 9, Vaqta |
| Biomerieux INC | $14.00 | 2024 | Vidas Nephrocheck |
| Astrazeneca Pharmaceuticals LP | $13.82 | 2025 | Airsupra |
| Antares Pharma, INC. | $12.78 | 2023 | Nocdurna, Xyosted, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.